Co-Diagnostics to Present at Medical Korea 2026

Core Insights - Co-Diagnostics, Inc. will participate in Medical Korea 2026, a significant healthcare conference in Seoul, South Korea, from March 19-22, 2026, alongside various Utah legislative and industry delegates [1][3] Group 1: Event Participation - Co-Diagnostics will engage in a healthcare business roundtable and present its upcoming Co-Dx PCR point-of-care platform during the conference [2] - The conference is expected to attract over 6,000 participants from more than 50 countries, featuring B2B introductions, presentations, and special sessions [2] Group 2: Strategic Importance - South Korea is identified as a priority partner for Utah, with efforts to strengthen trade and investment corridors between the two regions [3] - The World Trade Center Utah is organizing the delegation to enhance Utah's presence and partnerships within South Korea's healthcare ecosystem [3] Group 3: Conference Overview - Medical Korea 2026 serves as a premier platform for global healthcare collaborations, bringing together international healthcare leaders, government officials, and industry innovators [4] - The event aims to highlight emerging medical technologies and foster cross-border partnerships in healthcare and life sciences [4] Group 4: Company Overview - Co-Diagnostics specializes in molecular diagnostics, developing and marketing advanced diagnostic technologies that utilize nucleic acid detection and analysis [6] - The Co-Dx PCR platform, which includes various products, is currently under regulatory review and not yet available for sale [5][6]